AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00486330 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine, Tipranavir and ritonavir
Description: After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
Study NCT01057758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN
Description: Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
Study NCT01057758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
Study NCT04399525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine Single Dose
Description: Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study NCT04399525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Single Dose
Description: Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
Study NCT04399525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine Fourfold Dose
Description: Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
Study NCT04399525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Fourfold Dose
Description: Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
Study NCT03852836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultra-rapid acquisition of bile ducts images
Description: On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
Study NCT04555265 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency ablation or microwave ablation
Description: Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
Study NCT01241292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-901608 (Elotuzumab) 10 mg
Description: Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
Study NCT01241292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-901608 (Elotuzumab) 20 mg
Description: Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
Study NCT00382135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20mg tadalafil tablet taken by mouth once a day for 40 weeks
Study NCT00382135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 40 weeks
Study NCT02654587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02654587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT02676791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
Study NCT03038503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
Study NCT03038503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
Study NCT03662048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safe
Description: Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
Study NCT03662048 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safe
Description: Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
Study NCT00783887 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample of 5 ml
Study NCT02247050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
Study NCT00522990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT9283
Description: Three weekly intravenous administration of AT9283
Study NCT02026544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency Therapeutic Ultrasound
Description: 29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
Study NCT00467987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel
Description: androgel 1%
Study NCT00467987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04420624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
Study NCT00957658 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accolade® TMZF® Hip Stem
Description: Accolade® TMZF® Hip Stem
Study NCT02248506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clotrimazole
Description: All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
Study NCT02299219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Charge: Managing Cancer Online
Description: n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French.
Study NCT02299219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care and Cancer Resource Center
Description: The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments.
Study NCT01758237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser
Description: This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
Study NCT01758237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser Peripheral Iridotomy
Description: After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
Study NCT00078533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV CTL infusion
Description: Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
Study NCT00045916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High dosage electroconvulsive therapy
Description: Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
Study NCT00045916 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High dosage electroconvulsive therapy
Description: Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
Study NCT00045916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: Participants will receive nortriptyline.
Study NCT03302377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling & Fitbit
Description: Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
Study NCT00045916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will receive venlafaxine.
Study NCT00045916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.
Study NCT00045916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Participants will receive lithium.
Study NCT00605917 — intervention group
Intervention type: DRUG
Intervention: Sertraline hydrochloride
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration.
Study NCT03424850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: * Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 >90% (>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%
Study NCT01998243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB), group A
Description: the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
Study NCT01998243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet, control group B
Description: the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
Study NCT01998243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet, control group B
Description: the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
Study NCT02605252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: peginterferon alfa-2b 80 micrograms/week for 48 weeks
Study NCT02136303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
Study NCT02136303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
Study NCT02136303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S2: Kale extract versus kale purée
Study NCT02136303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S3: Kale extract: AMD-patients
Study NCT00045916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dosage electroconvulsive therapy
Description: Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
Study NCT03624140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood measurement
Description: Hemoglobin measurement
Study NCT03624140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse co-oxymeter (SpHb)
Description: non invasive method of hemoglobin measurement
Study NCT03624140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoCue
Description: non invasive method of hemoglobin measurement
Study NCT04189900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
Study NCT00424762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 6 months of treatment of blinded study drug
Study NCT00424762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: blinded treatment with matching placebo
Study NCT02426320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation Interruption Protocol
Study NCT02426320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sedation Protocol
Study NCT04277299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IcorySolution
Description: The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
Study NCT04056923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printing guided
Description: 3D printed navigational template guided
Study NCT04056923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided
Description: CT-guided
Study NCT04056923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: The results are shown by comparison of different colors.
Study NCT04056923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: The results are shown by comparison of different colors.
Study NCT04056923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative
Description: Preoperative localization.
Study NCT04056923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative
Description: Intraoperative localization.
Study NCT03652207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isomaltulose (Palatinose(TM)
Description: isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
Study NCT03652207 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
Study NCT01494662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HKI-272
Description: 240 mg orally, once daily
Study NCT01494662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
Study NCT01494662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
Study NCT01494662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HKI-272
Description: 160 mg orally, once daily
Study NCT01494662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ado-Trastuzumab Emtansine
Description: 3.6 mg/kg IV every 3 weeks
Study NCT01405924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine
Description: Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
Study NCT01405924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 RA
Description: 5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
Study NCT01405924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
Study NCT01405924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
Study NCT02301221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Study NCT02301221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and bowel lavage
Description: An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
Study NCT04322643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
Study NCT04322643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
Study NCT04322643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
Study NCT04322643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV over 30 minutes every 4 weeks
Study NCT04322643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 800 mg IV over 60 minutes every 2 weeks
Study NCT03665701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
Study NCT02087644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT003
Description: Injections
Study NCT02087644 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections
Study NCT01651949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9vHPV Vaccine
Description: 9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
Study NCT01651949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen